EFFECT OF AGE ON SINGLE-DOSE AND MULTIPLE-DOSE PHARMACOKINETICS OF ERYTHROMYCIN

被引:24
作者
MIGLIOLI, PA
PIVETTA, P
STRAZZABOSCO, M
ORLANDO, R
OKOLICSANYI, L
PALATINI, P
机构
[1] UNIV PADUA,DEPT PHARMACOL,LARGO E MENEGHETTI 2,I-35131 PADUA,ITALY
[2] UNIV PADUA,INST CLIN MED,I-35131 PADUA,ITALY
关键词
age effect; elderly subjects; erythromycin; pharmacokinetics; steady-state;
D O I
10.1007/BF00280051
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of age on the pharmacokinetics of erythromycin was investigated by comparing its kinetic behaviour in eight young healthy adults and eight healthy elderly subjects after single and repeated oral doses of erythromycin stearate 1 g b.d. for 7 doses. The peak serum concentration and area under the serum concentration-time curve (AUC) were significantly greater in the elderly subjects than in the young controls after single and multiple doses. Accordingly, the apparent oral clearance was lower in the elderly subjects (0.31 vs 0.64 and 0.22 vs 0.69 l·h-1·kg-1 after the first and seventh administration, respectively). The mean elimination half-life was significantly longer in the elderly group only after multiple dosing (4.8 vs 2.3 h). No age-related difference was observed in the time to peak serum concentration and apparent volume of distribution. The multiple-dose regimen resulted in an almost two-fold accumulation of erythromycin in the older individuals and no accumulation in the young adults. Mean drug accumulation in elderly subjects at steady state was 43% greater than was predicted from the AUC after the first dose, suggesting a time-dependent reduction in both systemic and presystemic clearance. The results indicate that the metabolic elimination processes for erythromycin are impaired in normal elderly subjects and suggest that caution is required on administering a high dose of it to aged people. © 1990 Springer-Verlag.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 17 条
[1]   INTERSUBJECT AND DOSE-RELATED VARIABILITY AFTER INTRAVENOUS ADMINISTRATION OF ERYTHROMYCIN [J].
AUSTIN, KL ;
MATHER, LE ;
PHILPOT, CR ;
MCDONALD, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (03) :273-279
[2]   PHARMACOKINETICS OF ERYTHROMYCIN ON REPETITIVE DOSING [J].
COLBURN, WA ;
DISANTO, AR ;
GIBALDI, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 17 (10) :592-600
[3]  
DANAN G, 1981, J PHARMACOL EXP THER, V218, P509
[4]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[5]  
GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081
[6]   DOSE-RELATED PHARMACOKINETICS AFTER ORAL-ADMINISTRATION OF A NEW FORMULATION OF ERYTHROMYCIN BASE [J].
JOSEFSSON, K ;
BERGAN, T ;
MAGNI, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (05) :685-691
[7]   EFFECTS OF ERYTHROMYCIN ON HEPATIC DRUG-METABOLIZING-ENZYMES IN HUMANS [J].
LARREY, D ;
FUNCKBRENTANO, C ;
BREIL, P ;
VITAUX, J ;
THEODORE, C ;
BABANY, G ;
PESSAYRE, D .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (06) :1063-1068
[8]  
LJUNGBERG B, 1987, REV INFECT DIS, V9, P250
[9]  
MATHER LE, 1981, BRIT J CLIN PHARMACO, V12, P131
[10]  
MERY JP, 1979, NEW ENGL J MED, V301, P944